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B cells carry out a central role in the pathogenesis of autoimmune disease. In addition
to the production of autoantibodies, B cells can contribute to disease development
by presenting autoantigens to autoreactive T cells and by secreting pro-inflammatory
cytokines and chemokines which leads to the amplification of the inflammatory response.
Targeting both the antibody-dependent and antibody-independent function of B cells
in adult rheumatic disease has led to the advent of B cell targeted therapies in clinical
practice. To date, whether B cell depletion could also be utilized for the treatment of
pediatric disease is relatively under explored. In this review, we will discuss the role of B
cells in the pathogenesis of the pediatric rheumatic diseases Juvenile Idiopathic Arthritis
(JIA), Juvenile Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis
(JDM). We will also explore the rationale behind the use of B cell-targeted therapies in
pediatric rheumatic disease by highlighting new case studies that points to their efficacy
in JIA, JSLE, and JDM.
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INTRODUCTION—B CELLS
The most well-defined function of B cells is their ability to produce antibodies as part of the
humoral immune response. However, other described roles of B cells in the immune system
have recently emerged including the ability to present both peptide and lipid antigens and to
produce an array of pro and anti-inflammatory cytokines (1–3). Following development in the
bone marrow where they undergo processes that aim to ensure tolerance, B cells are released
into the periphery as antigen-inexperienced cells. Upon activation and exposure to antigen, B
cells proliferate and differentiate into antibody-producing plasma cells or memory B cells, or,
depending upon the cytokine environment in which they find themselves, into cytokine-producing
B effector (Be) cells (For detailed information seeBox 1). Naïve B cells differentiate into Be-1, which
produce type 1 cytokines, or Be-2 cells, which produce type 2 cytokines, when co-cultured with
polarized T helper (Th)-1 or Th-2 cells, respectively (4). B cells can also produce immunoregulatory
cytokines such as IL-10, IL-35, and TGFβ (5, 6). Production of immunoregulatory cytokines by
B cells is usually attributed to a specialized subset of B cells known as regulatory B cells which
directly influence T cell function in humans by suppressing the differentiation of Th-1/Th-17 cells
and inducing the differentiation of T regulatory cells (Tregs) (5). B cell activation also leads to
the upregulation of molecules that mediate antigen-presentation, such as MHC class II (MHC
class II), or co-stimulatory molecules such as CD86/CD80. In some B cells, activation induces
class-switching, the process by which B cells change their immunoglobulin class from one to
another (i.e., IgM to IgG/IgA/IgE). All together, these diverse functions within the adaptive immune
response make B cells an important target for investigation in rheumatic disease.
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Murine models have now established that both antibody-
dependent and antibody-independent functions of B cells
contribute to development of experimental models of
autoimmune disease. Seminal examples include the observation
that B cell-deficient mice do not develop collagen-induced
arthritis (7), that CD80/CD86 expression on B cells is required
for autoreactive T cell activation and the development of arthritis
(8), and that chimeric mice lacking IL-10 expressing B cells
develop an exacerbated arthritis that is driven by an expanded
Th17 compartment (9). These data have now been translated
into human disease (10, 11). However, to date, the majority of
studies have focused on the role of B cell pathology in adult
rheumatic disease. Although these data have underpinned the
rationale for the advent of B cell depletion therapy in adult-onset
disease, there is comparatively a scarcity of studies investigating
whether a similar rationale could be applied to pediatric disease.
In this review, we will provide a broad overview of the current
evidence that B cell abnormalities drive aspects of pathology in
the most common pediatric inflammatory rheumatic diseases.
We will also summarize current case studies and clinical trials
demonstrating that targeting B cells in these diseases could be
invaluable, especially in patients whose disease is refractory to
first-line therapies.
JUVENILE IDIOPATHIC ARTHRITIS
Juvenile Idiopathic Arthritis (JIA) is an umbrella term that
encompasses a heterogenous group of conditions with a wide
spectrum of outcomes. The most common rheumatic disease in
childhood, JIA is characterized by joint swelling that lasts for
longer than 6 weeks and that develops before the age of 16, and
can cause significant disability and loss of quality of life if not
controlled (21). Within this group several subtypes of JIA exist,
including oligoarticular (oligo-JIA), polyarticular (poly-JIA),
enthesitis-related arthritis (ERA), psoriatic arthritis (PsA), and
systemic JIA (21), as defined by the International League of
Associations for Rheumatology (ILAR). At present there is no
cure for JIA, which means that current clinical strategy focuses
on achieving clinical remission (defined as no joint inflammation
and no secondary characteristics of disease such as rash, fever,
serositis and uveitis (22, 23). In the absence of clinical remission,
treatment is quickly escalated from the use of non-steroidal
anti-inflammatory drugs to include intra-articular steroids,
disease modifying anti-rheumatic drugs such as methotrexate,
and in the case of methotrexate failure to expensive biologic
therapies (24). The first-line biologic used in JIA treatment
is TNF inhibition, and despite being well-tolerated in many
children, there remains a subset of children whose disease
remain uncontrolled (25, 26). At present, therapeutic strategy is
defined by failure of medication in controlling disease severity as
there are no clinical or biological tools that allow stratification of
patients before treatment is started. Greater understanding
concerning the biological pathways underlying disease
development will improve stratification of patients and increase
early-remission rates.
Apart from systemic JIA, which is considered to be an
autoinflammatory disorder whose pathogenesis is thought to be
associated with IL-6 dysregulation and macrophage activation
(and will therefore not be discussed further in this review)
(21), the other subtypes of JIA are classically thought of
as autoimmune, T cell driven diseases. A particular role for
IL-17 producing T helper cells (Th17) has been postulated,
which may be particularly dominant in the extended oligo-
JIA and ERA forms of JIA (27, 28). However, subtypes
of JIA can also be characterized by different patterns of
auto-antibody production, which implicates a central role
for B cells in JIA pathogenesis. Further to autoantibody
production such as anti-nuclear antibodies (ANAs), B-cells
may contribute to disease pathogenesis by producing pro-
inflammatory cytokines and by presenting auto-antigens to
T-cells (29).
Autoantibodies
Anti-nuclear antibodies (ANA) are most commonly detected
in both oligo-JIA and rheumatoid factor (RF) negative poly-
JIA suggesting a B cell involvement in both patient groups.
Although the exact targets of these ANA are yet to be defined,
the presence of ANA provides strong evidence that B cell
tolerance is altered in both oligo-JIA and RF- poly-JIA. Indeed,
it is thought that ANA+ oligo-JIA and RF- poly-JIA patients
would be better considered as one subtype of disease based on
similarities in pathogenesis, risk for uveitis and early disease-
onset (30). ANA+ oligo-JIA and RF- poly-JIA are confined to
childhood and there is thought to be no equivalent in post-
pubertal patients (31, 32). While the contribution of ANA to
disease pathology remains unclear, recent research has suggested
that ANA positivity is associated with the development of ectopic
lymphoid tissue in certain JIA patients, which by facilitating
interactions between autoreactive T and B cells could directly
support the production of these autoantibodies (33). In contrast
to RF- poly-JIA, RF+ poly-JIA has a later onset, and many
clinical and genetic features (34) that are analogous with adult-
onset rheumatoid arthritis (RA), including the development
of anti-citrullinated (anti-CCP) and RF autoantibodies (35).
Furthermore, the multinational JIA consortium for Immunochip
(JACI) recently established that RF+ poly-JIA is more genetically
similar to adult-onset RA than to oligo-JIA and RF- poly-JIA
(34). This provides further evidence that these diseases are likely
to have similar underlying pathological mechanisms and that
current pharmacological strategies employed in RA are directly
relevant to RF+ poly-JIA. Although the detection of RF is used
diagnostically to subcategorize poly-JIA in RF- and RF+ patients,
anti-CCP antibodies are not standardly measured in clinical
practice in pediatric patients despite evidence from RA patients
suggesting that they may be useful in defining patients with more
severe clinical disease (36, 37). An autoantibody involvement,
and therefore B cell component, in the development of ERA
and PsA is much less well-defined, similarly to their adult-onset
counterparts Ankylosing Spondylitis and Psoriatic Arthritis,
respectively. Therefore, whether B cell depletion therapy would
convey much in the way of benefit for these diseases is yet to be
elucidated and as such are not routinely tested.
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Box 1 | Life Cycle of a B Cell
The earliest stages of B cell development occur in the bone marrow, which provides a specialized environment containing non-lymphoid cells such as osteolineage
cells and stromal cells. These cells support haematopoiesis and B cell development by secreting specific cytokines and growth factors such as IL-7, FLT3 ligand, stem
cell factor (SCF), RANKL and CXCL12 (12). In this specialized environment, repression of FLT3 in haematopoietic stem cells and induction of the master transcription
factor PAX5 commits these pluripotent cells to the B cell lineage as they differentiate into as pre-pro B cells. Movement through the early stages of B cell development
are defined by the re-arrangement of immunoglobulin (Ig) genes, which ultimately leads to the expression of a functional antigen-specific B cell receptor (BCR). Briefly,
Ig re-arrangement is initiated at the pro-B cell stage where the RAG-1/RAG-2 complex mediates recombination by inducing double strand breaks at recombination
signal sequences flanking the variable (V), diversity (D), and joining (J) regions of the heavy chain locus. RAG enzymes and accessory molecules then coordinate the
rejoining of V, D, and J segments, excising intervening DNA to give a single coding sequence that is ligated to the µ heavy chain locus. In frame rearrangements
that allow surface expression of a functional heavy chain in association with λ5 and V preB (the pre-B cell receptor) result in cessation of heavy chain rearrangement
and initiation of analogous Igκ rearrangement (13). Failure to produce a functional Igκ light chain following re-arrangement of the two Igκ light chain alleles leads to
re-arrangement of the alleles within the Igλ light chain locus giving a B cell four attempts to produce a functional BCR (14). It is at this stage that the BCR is tested for
autoreactivity, immature B cell undergo processes that ensue central tolerance by one of three processes: 1, receptor editing—immature B cells that react with low
to high avidity self-antigens can undergo receptor editing by a secondary rearrangement at the Igκ or rearrangement of the Igλ allele; 2, Clonal anergy—immature B
cells that react with low avidity self-antigen can migrate to the spleen as anergic B cells; 3, clonal deletion—immature B cells are deleted by apoptosis, which occurs
at a low rate for those cells that fail receptor editing (15). It is important to note that much of what we know about the early life cycle of a B cell is derived from mouse
studies and although informative there may be some differences, as yet undiscovered, in humans.
Once released from the bone marrow in humans, B cell subsets found in human peripheral blood can be broadly defined based on the expression of
CD19, CD20, CD24, CD38, IgD, and CD27. These peripheral subsets include antigen-inexperienced immature B cells (CD20+CD19+CD24+CD38+ IgD+) and
mature naïve B cells (CD20+CD19+CD24intCD38int IgD+) as well as antigen-experienced memory B cells (CD20+CD19+CD24+CD38− IgD−), plasmablasts
(CD20+CD19+CD24−CD38+ IgD−) and antibody-producing plasma cells (CD20−CD19−CD24−CD38+ IgD−) (16). Following activation with TLR-agonists, anti-
CD40 (which models T-B cell interactions in vitro) or pro-inflammatory cytokines (e.g., IFNα), antigen-inexperienced B cells can differentiate into IL-10 producing
regulatory B cells or depending upon the cytokine-polarizing environment differentiate into cytokine producing B effector cells (5, 17). Following activation and
encounter with antigen, activated B cells can also seed germinal centers (GC). Within a GC, the introduction of point mutations into the V regions B cell receptor
genes by activation-induced cytidine deaminase (AICD), a process called somatic hypermutation, and subsequent competition for antigen and survival signals from
T-follicular helper cells (TFH) by daughter B cells, a process called affinity maturation, promotes the expansion of B cells with high affinity ag-specific BCRs. Class
switching of BCRs to different isotypes, guided by the nature of the immune response etc can also occur in GCs (18). Following maturation in a GC, terminally
differentiated plasma cells can migrate back to the bone marrow where they can reside for up to the lifetime of the host (19, 20).The life cycle of a B cell and the
markers used to identify the various stages of B cell development by flow cytometry are summarized in Figure 1.
The underlying mechanisms that lead to auto-antibody
production in JIA are yet to be elucidated. Nevertheless,
current data suggests that altered peripheral B cell homeostasis
could be one contributing factor. CD5+ B cells, a potential
human equivalent of murine B-1a cells, are expanded in the
peripheral blood of patients with oligo-JIA and poly-JIA (38); B-
1 cells have polyreactive B cell receptors (BCR) that recognize
conserved sequences on bacterial pathogens and are therefore
enriched for autoreactive epitopes. CD5+ B cells in humans
are not as well-defined as there murine counterparts and
may also represent a population of pre-naïve B cells (39) or
activated B cells (40). There is also a reported expansion in
CD24hiCD38hi transitional B cells (41), a high proportion of
which still express polyreactive BCRs, as they are still undergoing
negative selection (42). These data suggest that B cell central
tolerance is abnormal in JIA, leading to autoreactive B cells
escaping negative selection to join the mature B cell pool.
This hypothesis is supported by data that critical checkpoints
in B cell tolerance are altered in JIA. For example, B cells
from JIA patients are still able to undergo receptor revision
in the periphery (43), a process usually restricted to the
bone marrow, which is accompanied by skewed lamba:kappa
light chain usage (44). Taken together, these data demonstrate
that changes in the frequency of potentially autoreactive B
cell subsets is accompanied with changes in the molecular
events that control B cell tolerance in JIA. Future studies are
needed to understand whether this directly contributes to the
production of autoantibodies and how this effects JIA pathology
in general.
Cytokine Production and
Antigen-Presentation by B Cells
As described above, B cells can also act as effectors of immune
response by presenting antigens and producing cytokines and
significantly, the CD24hiCD38hi transitional B cell compartment
which is altered in JIA also contains regulatory B cells;
CD24hiCD38hi transitional B cells produce the highest amount
of IL-10 following culture with agonistic anti-CD40 or CpG
(10, 45). A recent study has reported that IL-10 production
by CD19+CD24hiCD38hi B cells is reduced in a small cohort
of JIA patients (46). There was a drastic reduction in IL-
10+CD19+CD24hiCD38hi in peripheral blood compared to
controls, with an even greater reduction in synovial fluid
(46). Interestingly, an initial analysis of the difference between
RF+ and RF- JIA patients revealed that frequency of IL-
10+CD19+CD24hiCD38hi was lower in RF+ patients. It has
been previously published that CD19+CD24hiCD38hi Bregs are
drastically reduced in RA patients, and can no longer suppress
Th17 induction (11). These results strongly suggest that similarly
to their adult counterparts, that in RF+ JIA patients T cell
abnormalities may be at least in part driven by a dysfunctional
regulatory B cell compartment. Future functional studies are
needed to confirm this hypothesis.
In conjunction with a paucity of CD19+CD24hiCD38hi in
the synovial fluid of JIA patients (41), there is an expansion of
switched memory B cells in the synovial fluid B cell compartment
compared to the periphery. These switched memory B cells
are phenotypically defined as CD19+CD27+IgD− (41) and
express high levels of the transcript for IL-12p40. Importantly,
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FIGURE 1 | B cell development and activation in humans. B cells develop from hematopoietic stem cells generated in the bone marrow. Pro-B cells express a unique
antibody, the immunoglobulin (Ig) variable domain (Fv). They undergo re-arrangement of the heavy and light chains of this immunoglobulin (V-D-J and V-J
recombination) leading to the development of pre-B cells. A pre-B cell acquires antigen specificity by the expression of a unique BCR and surface IgM as it matures
into an immature B cell; at the this point the B cell under goes central tolerance by one of three processes: 1, receptor editing—immature B cells that react with low to
high avidity self-antigens undergo receptor editing by a secondary rearrangement at the Igκ or rearrangement of the Igλ allele; 2, Clonal anergy—immature B cells that
react with low avidity self-antigen can migrate to the spleen as anergic B cells; 3—clonal deletion: occurs at a low rate for those cells that fail receptor editing. If the
immature B cell survives central tolerance they develop into mature antigen-inexperienced naïve B cells. In the germinal centre B cells mature into memory and plasma
cells after antigen engagement. The GC produces memory and high affinity antibody-producing plasma B cells as a result of somatic hyper mutation, clonal expansion
and class switch recombination (CSR). Terminally differentiated plasma cells migrate back to the bone marrow and memory B cells produce antibody when they
encounter a secondary antigen.
switched memory B cells in the SF express higher levels of the
co-stimulatory molecules such as CD86 indicating an important
role in auto-antigen presentation by these cells at the inflamed
site (47). Indeed, B cells isolated from the synovial fluid of
patients with JIA are more efficacious at activating isolated
allogenic T cells in vitro compared to B cells isolated from the
peripheral blood (47). To date, whether switched memory B
cells differentiate in the joint or are recruited from the blood is
currently not known. A recent study has shown that switched
memory B cells expand at an increased rate in patients with oligo-
JIA and poly-JIA and that this expansion is inhibited by anti-
TNFα therapy (48). Based on these data, it could be postulated
that these cells are then recruited to the joint. Collectively,
evidence demonstrating that B cell abnormalities in JIA can be
found both in the periphery and at the inflamed site make B
cells an interesting target for therapy, particularly those patients
whose disease is refractory to current treatment protocols namely
non-responders to methotrexate and anti-TNFα therapy.
JUVENILE SYSTEMIC LUPUS
ERYTHEMATOSUS
Systemic lupus erythematous (SLE) is an autoimmune disease
characterized by the generation of auto-antibodies directed
against nuclear components. It can present with a wide
variety of symptoms including renal, musculoskeletal and
neuropsychiatric manifestations. The disease has a prevalence
of 50–100/100,000 people in the USA and Europe (49).
Patients who are diagnosed in childhood and adolescence
make up 10–15% of this population with highest rates of
diagnosis in female patients between 12 and 16 years (50).
The juvenile-onset form of disease has many similarities with
adult-onset SLE but there are some noteworthy differences
in clinical manifestation. Juvenile SLE (JSLE) has a more
severe disease course with higher rates of aggressive renal
disease, increased mortality rates when adjusted for age and
need a higher dose of glucocorticoids such as prednisolone
(49, 51). Glucocorticoids are the backbone of JSLE therapy,
with other DMARDs including hydroxychloroquine,
aziothioprine, sulfasalazine, mycophenolate mofetil, and
cyclophosphamide. For many young women, whose are
diagnosed pre or peri-pubertal, these drugs have life-changing
side-effects such as increasing the risk of osteoporosis,
increasing the risk in infertility problems and changes
in weight gain (52, 53). These side effects, coupled with
the increased in mortality rates and severity of disease,
demonstrate a clinically unmet need for therapeutics that
substantially improve both quality of life and reduce mortality in
pediatric patients.
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Autoantibodies
In the context of JSLE it is traditionally believed that
autoantibodies are pathogenic through the deposition of immune
complexes in the skin, renal glomerulus and sites of tissue
injury, in addition to targeting specific localized antigens.
More recently evidence suggests that autoantibodies act as
immune modulators through the recognition of nucleic acid
containing immune complexes that can directly induce cell
signaling and new gene transcription through endosomal toll-
like receptors (TLRs) (54). Thus, ANA positivity is a critical
characteristic used to define the development of SLE and is
observed in over 95% of cases. The importance of ANAs in
adult SLE has been extensively reviewed elsewhere (55, 56)
and due to the overlapping clinical spectra between pediatric
and adult onset disease these studies are extremely informative.
Both forms of the disease display positivity for a variety of
ANAs including those directed against double stranded DNA
(dsDNA) and extractable nuclear antigens (ENA) of which
examples include anti-Sm/RNP and anti-SSA/SSB (also known
as anti-Ro and anti-La autoantibodies) (55). There are however
some observed differences in autoantibody profiles between
the two diseases. It has been reported that there is a higher
prevalence of anti-dsDNA, anti-Sm and anti-RNP antibodies
in juvenile compared to adult SLE populations (57, 58), but
that significantly less JSLE patients present with anti-SSA and
anti-SSB antibodies (59). Whether these changes are caused by
differences in the severity of pathology between SLE and JSLE
remains unexplored.
Evidence on what causes the production of ANA in JSLE and
SLE can be garnered from genome-wide association scanning
(GWAS) studies. These studies have demonstrated that gene
susceptibility loci identified in lupus patients, which include
PTPN22, BTK, and LYN, are associated with the strength
of BCR signaling (60). Importantly, transgenic, congenic, or
knockout mice have demonstrated that modulation or deficiency
in molecules that control the strength of BCR signaling leads to
the productions of ANA and, in some cases, the development
of lupus-like disease. Polymorphisms in PTPN22, whose role in
BCR signaling is not well-defined, leads to hypo-responsiveness
following BCR activation, impairing B cell central tolerance by
diminishing both deletion and editing of autoreactive B cells
(61). Conversely, gain of function mutations in BTK (bruton’s
tyrosine kinase), a major adaptor of the BCR signaling cascade,
in transgenic mice leads to hyper-responsiveness of the BCR.
This reduces the activation threshold of the BCR leading to
spontaneous germinal center (GC) formation, a hallmark of
lupus-like disease inmice, andANAproduction due to ineffective
deletion of autoreactive B cells during central tolerance. Similarly,
mice with B cell specific deletion in Lyn, which is a negative
regulator of BCR activation, also develop anti-dsDNA and anti-
Sm antibodies, nephritis and spontaneous GC formation. These
examples demonstrate that changes to the strength of B cell
signaling impact activation, proliferation and both negative and
positive selection of B cells, all which could lead to systemic
autoimmunity in JSLE.
Autoimmunity in many mouse models of lupus is reversed
by deletion of the toll-like receptors (TLRs) or the TLR adaptor
protein Myd88. For example, in mice where there is a B cell
specific deletion of Lyn, they no longer develop nephritis if
Myd88 is also deleted. Other significant examples include the
observation that autoantibody profiles are altered in MRL/lpr
mice based on the deletion of either TLR7 and TLR9. In humans,
the TLR7 locus is found on the X chromosome suggesting
that changes to X chromosome inactivation in immune cells
may alter autoantibody profiles (62, 63). This is of interest as
the predilection of lupus to develop in females over males is
extremely high, over 90% of reported cases in adults are in
females, and is especially high in individuals that develop JSLE
after puberty. Future studies that stratify by sex and age are
needed to address the role of X chromosome inactivation in
autoantibody production and the onset of lupus nephritis. It
is important to note that TLR-activation can drive both the
terminal differentiation of plasma cells and memory cells and
that many SLE autoantigens can be detected by the endosomal
TLR compartment (64). Thus, a positive feedback loop may exist
whereby activation of TLRs/BCR in lupus by nuclear antigens
leads to the terminal differentiation of antinuclear B cells, which
in turn produce ANA and cause immune complex deposition
and antigenic spreading. Targeting these pathways are critical
when considering the development of therapeutics in both SLE
and JSLE.
Cytokine Production and
Antigen-Presentation by B Cells
The data summarized above demonstrate that B cell hyper-
reactivity in JSLE may be, in part, driven by endosomal TLR-
activation by nuclear-antigens. Of note, TLR-activation can
drive both the terminal differentiation of B cells and induce
cytokine production by B cells. In patients with active SLE,
TLR9 expression is increased on total B cells ex vivo (65).
Moreover, TLR9-activation in vitro leads to an altered cytokine
profile compared to healthy B cells which is characterized by
a reduction in TNFα, IL-10, and IL-6. This suggests that B
cells may be chronically activated in vivo (66). Studies have
also demonstrated that the regulatory B cell compartment is
abnormal is SLE, with a seminal study demonstrating that there
is an inability of CD24hiCD38hi B cells to produce IL-10 in
response to anti-CD40 stimulation and an inability to suppress
inflammatory T cell differentiation in vitro (10). More recently,
it has been established that exogenous cytokine production by
other cells of the immune system also impacts B cell cytokine-
production in lupus. Plasmacytoid dendritic cells (pDCs), which
are the highest producers of IFNα in the immune system, are
chronically activated during lupus leading to over-production of
IFNα in vivo, which skews the differentiation of B cells away
from regulatory B cells toward plasmablasts (45). These studies
have focused on total lupus cohorts, encapsulating both pediatric
and adult-onset patients. Future studies should stratify how B cell
cytokine production is affected by SLE age of onset. In one study
that did focus specifically on JSLE patients, it was shown that
there is increased mRNA and protein expression of TLR3, TLR7,
TLR9 in total peripheral blood mononuclear cells (PBMCs),
mirroring effects seen on isolated B cells from adult-onset lupus
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patients. In this study, it was proposed that B cells sense apoptotic
neutrophils via TLR-activation as a source of nuclear antigens
in JSLE, as blocking Myd88-dependent signaling suppress IFNα
production (67).
It is known that there are high serum levels of the B
cell activating cytokine Blys in JSLE patients (68). Although,
the cellular source of this Blys is unknown, it correlates with
disease severity marking a subset of childhood-onset patients
that develop a particularly severe form of disease (69). Studies
in mice have shown that high-levels of Blys allow autoreactive B
cells to escape deletion in the spleen and induce class switching
of antibodies without the need for T cell help. To date, there
is little research investigating the role of autoreactive T cells in
the development of lupus. However, in transgenic mice, B cell
specific deletion of MHCII, which prevents antigen-presentation
by B cells, reduces glomerular nephritis and reduces IFNγ
production by T cells (70). In this study, cognate TCR-Ag-
MHCII interactions between B cells and T cells drives both T
cell activation and further promotes B cell proliferation and
differentiation. Although the importance of antigen-presentation
by B cells is under-explored in SLE in humans, it has been
demonstrated that pro-inflammatory cytokine productions by T
cell is higher in patients with JSLE compared to age-matched
controls (71). It is therefore tempting to postulate that altered T
cell cytokine production is due to aberrant antigen-presentation
by B cells.
JUVENILE DERMATOMYOSITIS
Juvenile dermatomyositis (JDM) is a rare disease, yet the most
common form of childhood autoimmune myositis that presents
with proximal muscle weakness and associated skin rash.
The mainstay treatments for JDM are prednisolone and
methotrexate. Other immunosuppressive treatments currently
used includemycophenolate mofetil, cyclophosphamide (72) and
azathioprine. At present, there is limited evidence for biologic
therapy and its efficacy in the treatment of JDM due to limited
understanding of the mechanisms underlying disease pathology.
In general adult and juvenile onset DM share a similar clinical
and pathological phenotype. However, adult onset myositis
patients have much higher associated risk of malignancy (73),
a more chronic disease course and higher mortality rate. Key
pathological differences between adult and juvenile onset DM are
that JDM patients have increased risk of neovascularisation of
capillaries, up-regulation of MHC class I on myofibers and type I
interferon response (74). Investigating the functions of B cells in
JDM may provide an insight into the mechanisms of the disease
and lead to novel therapeutic pathways.
Autoantibodies
In approximately a third of JDM cases B-lymphocytes have
been detected in inflamed muscle, and almost 50% of patients
have detectable myositis-specific (MSA) or myositis-associated
autoantibodies (MAA) (75, 76). MSA andMAA can be identified
in the serum of up to 70% of JDM patients and closely correlate
to specific homogenous clinical phenotypes (Figure 2). In adult
myositis, the most frequent group of myositis autoantibodies
detected are the anti-synthetase enzymes. The anti-synthetases
are present in 25–40% of adult patients compared to 5%
of juvenile patients (75). Longitudinal studies have also
demonstrated that MSA phenotype and muscle biopsy score at
time of diagnosis can predict the risk of staying on treatment (77).
Thus, growing empirical evidence suggests that JDM patients
should be stratified based on autoantibody subtype to predict
both disease features, such as lung involvement or calcinosis, and
to inform treatment strategies employed by clinicians (78). MSA
and MAA also act as important diagnostic tools to discriminate
JDM from other rheumatic diseases such as JSLE and JIA that
can share some similar features of JDM, such as Raynaud’s
phenomenon and muscle weakness, and may lead to incorrect
diagnoses (78). These antibodies are also useful to differentiate
JDM from other rare immune-mediated myopathies such as
those associated with anti-signal recognition particle (SRP).
The underlying cause of MSA and MAA production in
JDM is yet to be elucidated. Although it has suggested
that there is aberrant expression of some MAA and MSA
targets, namely Jo-1 and Mi-2, on regenerating muscle fiber
in myositis patients when compared to controls (79). Given
the presence of these autoantigens, and that B cells have
long been detected in the inflamed muscle of myositis
patients (80), it may be that autoantigen specific B cell
differentiation occurs in the muscle in myositis. Prospective
studies that include the phenotyping of B cells recovered
from inflammatory infiltrates in JDM muscle should determine
whether this hypothesis is correct. Other targets of MSA and
MAA antibodies include members of the nucleic acid sensing
pathway (81). The connection between auto-antibodies against
nucleic acid sensing molecules and the IFN signature, which
is a hallmark of myositis immunopathology, is yet to be
ascertained. However, taken together these data strongly suggest
that aberrant sensing of nucleic acids is central in disease
pathogenesis by driving both IFN production and production
of autoantibodies against these molecules (82–84). Future work
will need to establish what causes auto-antibody production
against these molecules and what is the effect on B cell
differentiation/activation.
Cytokine Production and
Antigen-Presentation by B Cells
Due to the rarity of JDM cases, it is extremely hard to carry
out functional assays to understand what underlies B cell
dysfunction in JDM. Nevertheless, large cohorts of JDM patients
such as Juvenile Dermatomyositis Cohort Biomarker Study and
Repository (UK and Ireland) (JDCBS) and the Myositis Genetics
Consortium (MyoGen) are now being used to address how B cell
function is altered in children with JDM (85, 86). For example,
using patients recruited to the JDCBS, it was recently reported
that CD19+CD24hiCD38hi B cells are expanded in the peripheral
blood of JDM patients that are naïve of immunosuppressive
treatment, demonstrating that similarly to other rheumatic
disorders normal B cell development is affected. In this study, it
was also demonstrated that cytokine-production by immature B
cells is altered in JDM, exhibiting a pro-inflammatory phenotype
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FIGURE 2 | Myositis autoantibodies and their key clinical associations. JDM patients can be stratified by myositis specific and associated auto-antibodies (MSA/MAA)
to group with clinical phenotype. The anti-TIF1-γ and anti-NXP-2 autoantibodies are associated with calcinosis in JDM and malignancy in adults. The MDA5
autoantibody in juvenile cases is associated with mild muscle and skin disease, but strongly associated with interstitial lung disease (ILD). In adult IIM anti-Jo-1 is the
most common of the anti-synthetase autoantibodies and is associated with ILD, arthritis, fevers, Raynaud’s phenomenon and mechanic’s hand. The majority of
mortality in adult and children IIM patients is due to ILD. In rare cases treatment with statins can trigger an immune-mediated necrotizing myopathy that can be
characterized by the presence of an autoantibody against HMGCR, the pharmacological target of statins. ARD, autoimmune rheumatic disease; SRP, signal
recognition particle; HMGCR, 3-hydroxy-3methylglutaryl-conenzyme A reductase; TIF1, transcription intermediary factor 1; NXP2, nuclear matrix protein 2; MDA5,
melanoma differentiation-association gene 5; SAE, small ubiquitin-like modifier activating enzyme; 5NT1A, cytosolic 5′nucleotidase 1A; Mi-2, nucleosome-remodeling
deacetylase complex, Jo-1, histidyl tRNA synthetase; PL7, threonyl tRNA synthetase; PL12, ananyl tRNA synthetase; OJ, isoleucyl tRNA synthetases; EJ, glycyl tRNA
synthetase; KS, aspararginyl tRNA synthetase; Zo, phenylalanyl tRNA synthetase, Ha; tyrosyl tRNA synthetase; snRNP, small nuclear ribonucleic protein.
after activation through TLR7 and IFN-α (84). To our knowledge,
there is only one other report showing that cytokine production is
affected in JDM B cells. The data was presented as part of a larger
study comparing IL-10 production by B cells from children with
autoimmune disease with healthy controls. In this study, as part
of a collection with JSLE and undifferentiated or overlap (mixed)
connective tissue disease patients, JDM patients were shown to
have a reduced percentage of B10 cells; a population of regulatory
B cells that have been identified in human and mouse (87).
To date, there are no studies published that directly investigate
whether antigen presentation by B cells is altered in patients
with JDM. However, a GWAS study carried out by MyoGen
demonstrated that susceptibility of disease was associated with
SNPs within the MHC locus (88). Miller et al. have also reported
that risk of JDM development was particularly associated with
the HLA haplotype HLA-DRB1∗0301 (89). Future studies are
needed to directly understand how this affects auto-reactive T
cell activation by B cells in JDM and whether this is altered
in different autoantibody subtypes. Greater understanding of
the B cell component that underlies JDM pathogenesis will
provide evidence for the efficacy of B cell-targeted-therapies for
this disease.
B CELL TARGETED-THERAPIES IN
PEDIATRIC RHEUMATIC DISEASE
B Cell Depletion Therapy
The most well-known and widely used B cell depletion therapy
for the treatment of rheumatic disease is Rituximab. This
chimeric monoclonal antibody targets the surface protein CD20
expressed mainly by memory and naïve B cells and results
in depletion by antibody-dependent cytotoxicity, complement-
mediated lysis or apoptosis (90). Table 1 summarizes the B cell
depletion therapeutic agents that have been trialed in pediatric
rheumatological diseases. The original rationale for treatment
of adult patients with rheumatoid arthritis with rituximab, circa
1998, was that depletion of the memory B cell compartment
would influence immune cell interactions that could potentially
“re-set” immunological tolerance as crucially auto-antibody
producing plasma cells no longer express CD20 (94). Although
the actual picture is more complicated, numerus randomized
trials have now confirmed that B cell depletion therapy with
rituximab has some beneficial effects in the treatment of
adult disease.
Despite failing to meet primary endpoints in two large
double-blind randomized, placebo-controlled trials investigating
both renal [LUNAR (91)] and non-renal [EXPLORER (95)]
manifestations of SLE in adults, rituximab has been subsequently
demonstrated as a potentially effective treatment in both adults
and children with refractory disease (96). Although not currently
approved by the UK national institute of clinical excellence
(NICE), rituximab can be prescribed at the discretion of the
treating physician on the basis of a specialist NHS England
interim commissioning policy. It has been suggested that both
LUNAR and EXPLORER trials may have failed to demonstrate
efficacy for a number of reasons including problems with
the study design, which is frequently quoted in the cases
of clinical trials investigating the efficacy of new therapeutics
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in SLE. Factors including high background steroid doses in
the control group and issues with end-point measurements
are likely to have contributed to this. It is important to
note that evidence from animal models suggests that lupus-
prone MRL mice are surprisingly refractory to B cell depletion
due to high levels of serum IgG inhibiting FcγR-dependent
phagocytosis by macrophages and neutrophils (97). Further
studies are needed to understand whether lupus patients that
do not respond to B cell depletion therapy have a similar
acquired deficiency in their myeloid compartment caused
by the burden of endogenous auto-antibody associated with
disease pathology.
For pediatric rheumatic disease, very few formal trials
exist that have investigated the efficiency of B cell depletion
therapy in suppressing disease symptoms. In spite of this,
Rituximab is increasingly being used as an adjunctive therapy
to treat children with JIA, JDM and JSLE. Importantly, despite
the well-established use of Rituximab in RA, it is currently
infrequently used as a biologic in RF+ poly-JIA, which, as
discussed above, is thought of as the early-onset equivalent
of RA. Future clinical trials are essential to establish its place
in the clinician’s therapeutic arsenal in the treatment of RF+
poly-JIA. In terms of oligo-JIA and RF- poly-JIA, especially
those that have ANA, there is considerable evidence that
rituximab treatment may be a worthwhile treatment option.
Several case studies have demonstrated that rituximab therapy
can produce sustained clinical improvement in patients with
refractory disease (98–100). Currently, rituximab is often only
considered following the failure of first-line treatments such as
TNF inhibitors and methotrexate in both pediatric and adult
disease. Taking-into-account the strong B cell signature observed
in JIA patients with early-onset disease, rituximab treatment
could potentially benefit these patients if used prior to failure
to first-line therapies and could therefore prevent sustained
disability as a result of established joint damage in some of
these patients.
In JSLE, a retrospective cohort study recently reported that
the use of rituximab for the treatment of active or refractory
disease is increasing. There is increasing evidence to support
that this treatment is effective in reducing specific disease
activity biomarkers in SLE. Rituximab has been shown to reduce
steroid use (and therefore importantly decrease the incidence
of side-effects associated with long term corticosteroid use) in
those not responding to standard therapies (101). It has been
suggested that adverse reactions to rituximab are increased in
JSLE patients compared to adult-onset SLE patients’ (102). For
example, half the children recruited to a small study in France
reported by Willems et al. developed thrombocytopenia and
neutropenia following treatment. However, it is often difficult
to distinguish what findings are a result of side effects to
treatment with rituximab and what may be attributed to an
underlying disease flare (102). In comparison, another small
study by Marks et al. (103) reported no side-effects or adverse
reactions. This highlights the need for larger studies to prevent
sampling bias and to establish the safety profile and efficacy
of rituximab in childhood onset disease. Problems with study
design in adult SLE, which include the treatment of rituximab
alongside many other medications and lack of an appropriate
control group, are also present in JSLE. Appropriate trials in
adults and children are now required as the subtle immunological
differences observed between SLE and JSLEmeans that rituximab
treatment may have a different efficacy in disease depending on
age of onset.
One of the few pediatric diseases where rituximab has been
trialed is in JDM, in a study by Oddis et al. where efficacy in adult
DM and JDM were compared (92). Although the primary end
point of the randomized control trial was not met, Oddis et al.
showed that a higher proportion of JDM patients (87%) treated
with rituximab met the definition of improvement more quickly
than adult dermatomyositis (ADM) patients (78%). These results
might imply that B cells in JDM are either more pathogenic than
in ADM, or perhaps B cells have a greater regulatory role in
ADM compared to JDM. Future studies are needed to address
these differences.
It is important to note that some patients with pediatric
rheumatic disease are refractory to first-line therapies and thus
may require monoclonal antibody therapy, such as rituximab.
Clinical trials that directly compare rituximab therapy with
methotrexate alone, TNF inhibiting drugs or, where appropriate,
anti-IL-6 therapy would be extremely informative to help stratify
treatment efficacy when compared to other current treatment
strategies. Development of other CD20-targeting monoclonal
antibodies is ongoing, recent additions include ofatumumab
(104) and veltuzumab, which have a similar mechanism of
action to rituximab. Notably, ofatumumab is a fully humanized
form of CD20, which has been demonstrated to be effective in
adults and children with SLE who have had adverse reactions to
rituximab (104).
Other B Cell-Targeting Therapies
Further to B cell depletion therapy, there are other biologics
in clinical practice with a method of action that targets B
cell activation/function (Figure 3). The most well-known of
which are Belimumab (a monoclonal antibody that inhibits
BAFF/Blys) and Abatacept (which binds CD28 on T cells
thus preventing its interaction with CD80/CD86 on antigen-
presenting cells such as B cells). Data demonstrating that
Blys levels in the sera differ between JIA and JSLE patients
suggests that Belimumab treatment may be more efficacious
in diseases that have higher levels of BAFF such as JSLE.
Belimumab is currently FDA approved for the treatment of adult-
onset SLE and there is currently an ongoing trial in pediatric
lupus (PLUTO – NCT01649765) to investigate the safety and
pharmacokinetics of this treatment in disease. Although PLUTO
is yet to report, there is an abstract reporting that background
steroid treatment was tapered in 63% of JSLE patients treated
with Belimumab suggesting a favorable effect on disease (93).
To our knowledge, similar studies do not yet exist in JIA
or JDM.
Abatacept is primarily thought of as a drug that targets
T cell function by preventing its interaction with antigen-
presenting cells, which include both B cells and dendritic cells
(DCs). Importance of B cells in the efficacy of abatacept-
treatment is demonstrated by studies showing that in RA patients
Frontiers in Immunology | www.frontiersin.org 9 February 2019 | Volume 10 | Article 214
Wilkinson and Rosser B Cells in Paediatric Rheumatic Disease
FIGURE 3 | B cell-targeted therapeutics. There are three main categories of B
cell targeting therapeutics. (A) Chimeric monoclonal antibodies against CD20
(e.g., rituximab) which target B cells for depletion by antibody-dependent
cytotoxicity, complement-mediated lysis or apoptosis. (B) Monoclonal
antibodies that bind B cell activating factor/B-lymphocyte stimulator
(BAFF/BLyS) (e.g., Belimumab) preventing B cell proliferation and survival.
(C) Abatercept, a fusion protein of CTLA-4 and a fragment of the modified Fc
domain of human IgG1, that binds to CD28 on T cells preventing the
interaction with CD80/CD86 on antigen-presenting cells inhibiting T cell
activation and differentiation.
abatacept-treatment is dependent upon the baseline levels of
memory B cells (which express higher levels of CD80/CD86)
(105, 106). There is also some evidence that abatacept inhibits
phosphorylation of Syk in PB B cells fromRApatients, potentially
directly altering intracellular signaling cascades which affect
B cell activation and proliferation (107). Although, abatacept
treatment is likely to affect multiple immune cell subsets,
these data demonstrate a decisive effect of this drug on the
B cell compartment.
At present, in the UK, NICE only recommends Abatacept
treatment for poly-JIA patients who are over 6 years of age, whose
disease has not responded to treatment with a disease-modifying
anti-rheumatic drug (DMARD) or at least one TNF inhibitor.
This means to date that no studies have directly compared the
efficacy on abatacept to drugs such as adalimumab and etanercept
as clinical trials have focused on patients that have failed TNF
therapy (108). The safety profile of Abatacept is thought to be
generally good and studies have demonstrated that there is a
favorable response in 70% of patients. Studies have also suggested
a possible efficacy in oligo-JIA patients with Uveitis who have also
failed TNF inhibition therapy (109). In the future, it should be
possible to target patients that have mutations in PTPN22, a JIA
susceptibility locus, which encodes a tyrosine phosphatase that
downregulates CD28 activation (110). These patients are likely to
fall across all JIA subtypes.
The efficacy of Abatacept treatment for JSLE and JDM
is much less well-defined. Indeed, all trials investigating its
efficacy of Abatacept in adult-onset SLE have not reached their
primary end-point, although this is likely to be to problems in
clinical trial design in lupus, similarly to those conducted with
Rituximab, as there is some evidence it suppresses the severity
of nephritis (101). In JDM, there is a case study suggesting
that Abatacept-treatment suppresses recalcitrant disease that is
complicated by calcinosis formation and there is a phase 4
interventional clinical trial (NCT02594735) underway to assess
the safety and efficacy of subcutaneous abatacept in 10 patients 7
years of age and older with refractory JDM (111). Future work
is necessary to establish its efficacy in both juvenile SLE and
DM patients.
CONCLUDING REMARKS
B cell depletion therapy has improved the lives of many
patients with adult-onset autoimmune rheumatic disease. The
data summarized above demonstrate that B cell dysfunction is
also central to the pathology of many patients with pediatric-
onset rheumatic disease. However, due to inherent problems
in the design and approval of clinical trials focused on
pediatric-onset disease, the understanding of the efficacy of
B cell depletion/targeting therapies is years behind that of
adult rheumatic disease. The future of clinical practice will
be centered around the stratification of patients and the
increased cost-efficiency of multi-omics platforms means the
age of personalized medicine is fast approaching. We propose
that future stratification of JSLE, JDM, and JIA will identify
a subset of patients whose disease is driven by a B cell
component, which makes them ideal candidates for B cell
depletion/targeting therapies, and that treatment protocols will
be applied which define patients by immune-phenotype rather
than by clinical manifestation. For these changes in clinical
practice to take place, correctly controlled clinical trials must be
performed that assess the safety, efficiency and pharmacokinetics
of B cell targeting biologics in children, which is likely to
be drastically different to adults. In particular, the effect of
these drugs on the immature immune system should be
addressed. This will provide information on particular drug
profiles, but will also provide information on the processes
underlying B cell development in early-life. Notably, there
are relatively few studies that have carried out consensus
B cell phenotyping in pre and peri-pubertal individuals.
Moreover, to date, there are no studies that stratify B cell
responses in children and young people by sex, despite an
appreciation that there is a sex-biased development of rheumatic
disease in women. Future studies are needed to improve the
characterization of basic B cell biology in healthy children and
those with autoimmune disease, which will aid the understanding
of the usefulness of B cell depletion therapy in pediatric
rheumatic disease. We believe this will allow current treatment
protocols to be updated so that they more effectively target
the “window-of-opportunity” based on immune-phenotype,
hopefully preventing long-term disability in children with
musculoskeletal disease.
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